You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥-B(01672.HK):同類首創治療肥胖症的減重不減肌候選藥物ASC47在澳大利亞進行的臨牀I期研究取得積極結果
格隆匯 11-07 19:19

格隆匯11月7日丨歌禮制藥-B(01672.HK)公吿,其用於治療肥胖症的同類首創、減重不減肌候選藥物ASC47在澳大利亞進行的低密度脂蛋白膽固醇(LDL-C)偏高受試者I期單劑量遞增(SAD)研究(NCT06427590)的頂線結果。

在接受皮下注射超長效ASC47的LDL-C偏高受試者(LDL-C>110mg/dL(2.8mmol/L))中,ASC47顯示出了長達21天的半衰期,支持在肥胖症患者中每月給藥一次。此外,在單次皮下注射後的第29天,ASC47靶向結合良好,表現為脂質生物標誌物仍有顯著降低。

基於在LDL-C偏高受試者中開展的ASC47單藥SAD研究的安全性、藥代動力學和靶向結合數據,第二項I期研究(ASC47單藥在肥胖症患者中的SAD研究)已在澳大利亞開展。預計將於2025年第一季度獲得頂線數據。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account